Once-daily Dolutegravir (DTG; S/GSK1349572) is Non-inferior to Raltegravir (RAL) in Antiretroviral Naive Adults. 48 Week Results from SPRING-2 (ING113086)

Authors
Category Primary study
Conference19th International AIDS Conference (AIDS 2012); 2012 Jul 22-27; Washington, DC, United States.
Year 2012
This article has no abstract
Epistemonikos ID: 92f6ef5035a09420f03a7ef416a53ecb791a695e
First added on: Apr 18, 2022